Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$27.2M | -$37.8M | -$20.8M | -$17.0M | -$18.0M | -$17.2M | -$23.1M | -$16.8M | -$21.6M | -$17.3M |
| Net income | -$18.1M | -$35.4M | -$20.5M | -$16.8M | -$17.1M | -$17.4M | -$17.7M | -$10.0M | -$19.8M | -$17.3M |
| EPS (diluted) | -$0.02 | -$0.03 | -$0.01 | -$0.01 | -$0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.6M | -$31.6M | -$22.8M | -$12.9M | -$17.0M | -$18.8M | -$21.5M | -$16.4M | -$12.6M | -$10.6M |
| Capital expenditures | $54.8K | $36.9K | $0.00 | $0.00 | — | — | — | — | — | — |
| Free cash flow | -$24.7M | -$31.6M | -$22.8M | -$12.9M | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.1M | $28.1M | $5.45M | $6.15M | $14.1M | $9.36M | $13.3M | $3.85M | $0.00 | $0.00 |
| Total assets | $45.9M | $29.1M | $8.03M | $8.23M | $14.6M | $11.6M | $13.8M | $4.36M | $50.6M | $47.9M |
| Total liabilities | $11.8M | $11.9M | $4.92M | $3.39M | $5.22M | $6.09M | $12.0M | $4.58M | $28.3M | $19.6M |
| Shareholders' equity | $34.1M | $22.2M | $4.37M | $7.60K | $9.38M | $5.55M | $1.79M | -$229K | $22.2M | $28.3M |
| Retained earnings | -$74.9M | -$110M | -$127M | -$149M | -$182M | -$200M | -$217M | -$227M | -$247M | -$265M |
| Shares (wtd avg diluted) | 1.18B | 1.25B | 1.54B | 1.83B | 3.16B | 4.29B | 6.24B | 9.79B | 23.9B | 67.3B |
Every figure is extracted from Akari Therapeutics Plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.